Fate Therapeutics, Inc.

NASDAQ:FATE

Biotechnology

Healthcare
$1.05 -0.00%

-$0.00 today

Market cap
$122.39M
Beta
2.52
P/E (TTM)
-1.8
EPS (TTM)
-$1.08
52W Low $0.91High $2.88

Volume 1.87M

Average 2.92M

FATE Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Fate Therapeutics, Inc.NASDAQ: FATE

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $3.93M fell 46.8% year over year, behind the -43.3% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 28.9% from the prior quarter. Over 3 fiscal years it compounded at -31.8% a year.

Context

  • Stock-based compensation amounted to 375.0% of revenue in FY2025, up 70.6 pp from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -46.8% toward the trailing-twelve-month pace of -43.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.93M-28.9% QoQ
Last fiscal yearDec 2025
$24.92M-39.9% YoY
LTMMar 2026
$21.47M-43.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-46.8%——
1 year-39.9%——
3-year CAGR-31.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
24.92M USD
Year-over-year change
-39.9%
4-year CAGR
-17.7%

Stock-Based Compensation vs competitors

How FATE compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -43.3% is the 6th highest of 10, against a peer median of -22.0%.
  • Stock-based compensation amounts to 340.0% of revenue for FATE, versus a peer median of 87.7%.
FATE Competitors
Stock-Based Compensation for FATE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VORVor Biopharma Inc.LTM Mar 2026$27.69M USD+218.3%+20.9%—
FATEFate Therapeutics, Inc.LTM Mar 2026$21.47M USD-43.3%-31.8%340.0%
ALECAlector, Inc.LTM Mar 2026$21.22M USD-43.4%-16.7%115.2%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$10.08M USD-60.8%-22.0%60.3%
PEPGPepGen Inc.LTM Mar 2026$10.03M USD-22.0%+30.6%—
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$9.77M USD+1.5%+47.6%—
NKTXNkarta, Inc.LTM Mar 2026$7.62M USD-49.8%-20.2%—
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$6.49M USD-5.6%+3.2%—
MOLNMolecular Partners AGLTM Mar 2026CHF 4.21M CHF-4.1%-4.6%—
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$3.06M USD-44.1%-45.0%—
Peer median (excluding FATE) —-22.0%-4.6%87.7%

Competitors are the stored peer set for FATE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(212.15M)(281.72M)(160.93M)(186.26M)(136.32M)
Depreciation & Amortization5.85M13.76M18.28M18.96M9.3M
Deferred Income Tax00000
Stock-Based Compensation54.36M78.73M43.46M41.5M24.92M
Change in Working Capital2.1M(34.71M)19.18M(1.96M)(3.74M)
Accounts Receivables(3.16M)(29.8M)36.65M(1.11M)2.62M
Inventory00000
Accounts Payables014.25M(28.94M)(1.66M)(9.03M)
Other Working Capital5.26M(19.16M)11.47M816K2.66M
Other Non-Cash Items(13.03M)(24.27M)(52.26M)4.89M(247K)
Operating Cash Flow(162.87M)(248.21M)(132.26M)(122.87M)(106.08M)
Capital Expenditures(50.7M)(35.57M)(6.15M)(730K)(5.95M)
Acquisitions (Net)0000362K
Purchases of Investments(968.16M)(404.8M)(358.81M)(317.75M)(195.14M)
Sales of Investments694.84M607.11M477.63M330.7M311.9M
Other Investing Activities00000
Investing Cash Flow(324.02M)166.75M112.67M12.22M111.17M
Debt Repayment00000
Common Stock Issued411.74M9.21M85K94.82M0
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities41.39M005.07M5.49M
Financing Cash Flow453.13M9.21M85K99.89M5.49M
Effect of Forex Changes0050K4.95M0
Net Change in Cash(33.76M)(72.25M)(19.46M)(5.81M)10.57M
Free Cash Flow(213.57M)(283.77M)(138.42M)(123.6M)(112.04M)

Fate Therapeutics, Inc.

NASDAQ:FATE

Intrinsic Alpha fair value

Locked

Current Price

$1.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.